Literature DB >> 14513224

[Complications of transrectal prostate biopsy. Determination of current status].

H W Gottfried1, B Volkmer.   

Abstract

The procedure for prostate biopsy has undergone a dramatic change in the last 2 decades. The introduction of PSA into diagnostics for prostate carcinoma and simultaneous development of modern biopsy techniques have led to a marked increase in transrectal prostate biopsies. At the same time, serious complications have become less frequent. Grave complications after biopsy include septic complications (approximately 1%), rectal hemorrhages (approximately 0.1%), and ischurias (0.5%). Less severe complications such as occurrence of fever without septic signs account for 3.5%. One of the frequent complications that usually do not require treatment is gross hematuria, which is observed in nearly 50% of all patients. The same applies to hematospermia with a similar frequency.In the rare cases of the altogether serious complications after prostate biopsy, appropriate action is essential. All in all, prostate biopsy nowadays represents a safe diagnostic procedure with few complications and an extraordinarily high level of usefulness for everyday urological practice.

Entities:  

Mesh:

Year:  2003        PMID: 14513224     DOI: 10.1007/s00120-003-0400-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  31 in total

1.  Transrectal needle method for biopsy of the prostate: review of 90 cases.

Authors:  E B Ostroff; J Almario; H Kramer
Journal:  Am Surg       Date:  1975-10       Impact factor: 0.688

2.  Minimal invasive therapy of prostatic abscess by transrectal ultrasound-guided perineal drainage.

Authors:  R Bachor; H W Gottfried; R Hautmann
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

3.  Transrectal biopsy of the prostate and bacteraemia.

Authors:  P M Thompson; R W Talbot; D A Packham; C Dulake
Journal:  Br J Surg       Date:  1980-02       Impact factor: 6.939

4.  The problem of infection after prostatic biopsy: the case for the transperineal approach.

Authors:  P M Thompson; J P Pryor; J P Williams; D E Eyers; C Dulake; M F Scully; V V Kakkar
Journal:  Br J Urol       Date:  1982-12

Review 5.  Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.

Authors:  B Djavan; M Waldert; A Zlotta; P Dobronski; C Seitz; M Remzi; A Borkowski; C Schulman; M Marberger
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

6.  Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.

Authors:  René Raaijmakers; Wim J Kirkels; Monique J Roobol; Mark F Wildhagen; Fritz H Schrder
Journal:  Urology       Date:  2002-11       Impact factor: 2.649

Review 7.  Massive rectal bleeding following transrectal ultrasound-guided prostate biopsy.

Authors:  E Brullet; M C Guevara; R Campo; J Falcó; J Puig; A Prera; J Prats; J Del Rosario
Journal:  Endoscopy       Date:  2000-10       Impact factor: 10.093

8.  Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores.

Authors:  C K Naughton; D K Ornstein; D S Smith; W J Catalona
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

9.  Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy.

Authors:  D A Kapoor; I W Klimberg; G H Malek; J D Wegenke; C E Cox; A L Patterson; E Graham; R M Echols; E Whalen; S F Kowalsky
Journal:  Urology       Date:  1998-10       Impact factor: 2.649

10.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.

Authors:  K K Hodge; J E McNeal; M K Terris; T A Stamey
Journal:  J Urol       Date:  1989-07       Impact factor: 7.450

View more
  1 in total

1.  [Spondylodiscitis caused by septicemia after transrectal prostate biopsy. An extremely rare complication--case report].

Authors:  A Majoros; D Bach; P Ostermann; A Amiri-Sani
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.